Select a community
ALS including PLS and PMA
Find out more about the PatientsLikeMe
ALS Community
Home > Community Treatment Reports > Montelukast Treatment Report
What is Montelukast?

Montelukast is in a class of medications called leukotriene receptor antagonists (LTRAs). It works by blocking the action of substances in the body that cause the symptoms of asthma and allergies. Read more...Click to read more below

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Other 6 0
Asthma 5 1
Allergies 4 0
Nasal congestion 1 0
Fatigue 1 0
disease-related symptoms 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
0 0%
Mild
0 0%
None
1 100%

Dosages

  daily 4 mg daily 10 mcg daily 10 mg daily 25 mg daily 30 daily 200 mg daily
  3 Number of Patients: 3 2 Number of Patients: 2 1 Number of Patients: 1 8 Number of Patients: 8 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Montelukast (multiple reasons could be selected)
Reason # Patients Percentage of patients
Doctor's advice
2 67% Doctor's advice: 67%
Did not seem to work
1 33% Did not seem to work: 33%
Other
1 33% Other: 33%

See all 3 patients who’ve stopped taking Montelukast

Currently Taking Montelukast

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
1
0
1
6
2

Stopped Taking Montelukast

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
1
1
1

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
0 0%
Usually
1 100%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
0 0%
Not at all
1 100%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
1 100%
< $25
0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 23, 2009.